Abilify MyCite combines Otsuka’s aripiprazole, a drug used to treat schizophrenia, bipolar disorder and depression, with an ingestible sensor produced by Proteus Health. The sensor records when ...

Two companies that have been blazing a trail in this field are Otsuka Pharmaceutical Company and Proteus Digital Health, with the co-developed Abilify MyCite (aripiprazole tablets with sensor ...

Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over TA1054 15 April 2025 15 April 2025 ...

Quetiapine XR was administered at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per ...